Last reviewed · How we verify
NCT02844335
Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer
Phase 1, PHASE2 trial testing Cryosurgery in Breast Cancer Recurrent in 60 participants. Completed in 1 July 2019.
1 July 2017
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 July 2016 |
| Primary completion | 1 July 2017 |
| Estimated completion | 1 July 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Cryosurgery
- NK immunotherapy — full drug profile →
Conditions studied
- Breast Cancer Recurrent — all drugs for Breast Cancer Recurrent →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 30 to 70, any sex, with Breast Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced breast cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
NK cell-based cancer immunotherapy: from basic biology to clinical development.
Liu S, Galat V, Galat Y, Lee YKA, et al · · 2021 · cited 504× · PMID 33407739 · DOI 10.1186/s13045-020-01014-w -
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038 -
Immunotherapeutic interventions of Triple Negative Breast Cancer.
Li Z, Qiu Y, Lu W, Jiang Y, et al · · 2018 · cited 99× · PMID 29848327 · DOI 10.1186/s12967-018-1514-7 -
Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.
Yakkala C, Chiang CL, Kandalaft L, Denys A, et al · · 2019 · cited 67× · PMID 31608067 · DOI 10.3389/fimmu.2019.02283 -
Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
Fournier C, Martin F, Zitvogel L, Kroemer G, et al · · 2017 · cited 55× · PMID 29147628 · DOI 10.1080/2162402x.2017.1363139 -
Photodynamic Therapy and Hyperthermia in Combination Treatment-Neglected Forces in the Fight against Cancer.
Bienia A, Wiecheć-Cudak O, Murzyn AA, Krzykawska-Serda M. · · 2021 · cited 36× · PMID 34452108 · DOI 10.3390/pharmaceutics13081147 -
The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy.
Abakushina EV, Popova LI, Zamyatnin AA, Werner J, et al · · 2021 · cited 29× · PMID 34835294 · DOI 10.3390/vaccines9111363 -
Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.
Sabry M, Lowdell MW. · · 2020 · cited 21× · PMID 32416056 · DOI 10.1002/sctm.19-0423
Verify or expand the search:
- PubMed search for NCT02844335
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cryosurgery
Trials testing the same drug.
- NCT06593106 — Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial · NA · recruiting
- NCT04429204 — Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma · NA · withdrawn
- NCT04693377 — Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T · NA · recruiting
- NCT04249167 — Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer · EARLY_PHASE1 · withdrawn
- NCT04150939 — Cryoablation for the Treatment of Metastatic Cancer · NA · active not recruiting
Other recruiting trials for Breast Cancer Recurrent
Currently open trials in the same condition.
- NCT06799065 — First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl · Phase 1 · recruiting
- NCT06659146 — Thermotherapy in Addition to SOC Palliative Radiotherapy · NA · recruiting
- NCT06458413 — Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer · Phase 2 · recruiting
- NCT05592938 — Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) · NA · recruiting
- NCT05730608 — 18F-FDG PET/CT Imaging for Breast Cancer · NA · recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02844335 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 12 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02844335.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing